{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:09:21Z","timestamp":1781021361598,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.eururo.2012.09.007","type":"journal-article","created":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T14:01:59Z","timestamp":1347372119000},"page":"927-935","source":"Crossref","is-referenced-by-count":62,"title":["A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study"],"prefix":"10.1016","volume":"63","author":[{"given":"Laurence H.","family":"Klotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Y.","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Kebabdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.09.007_bib0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.007_bib0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.20388","article-title":"Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy","volume":"101","author":"Krupski","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.09.007_bib0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.09.007_bib0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.007_bib0025","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0030","first-page":"2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2012.09.007_bib0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","article-title":"Androgen deprivation therapy for prostate cancer results in significant loss of bone density","volume":"54","author":"Wei","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.007_bib0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.007_bib0050","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0055","first-page":"4908","article-title":"Fracture risk in androgen deprivation therapy: a Canadian population based analysis","volume":"16","author":"Lau","year":"2009","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0060","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2012.09.007_bib0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1078155211402105","article-title":"Bone health management in prostate cancer patients receiving androgen deprivation therapy","volume":"18","author":"Dhanapal","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.eururo.2012.09.007_bib0070","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older","volume":"337","author":"Dawson-Hughes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.007_bib0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s11606-007-0291-4","article-title":"Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy","volume":"22","author":"Yee","year":"2007","journal-title":"Gen Intern Med"},{"key":"10.1016\/j.eururo.2012.09.007_bib0080","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0085","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.09.007_bib0090","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.007_bib0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2012.09.007_bib0100","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0105","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1464-410X.2009.08622.x","article-title":"Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy with severe osteopenia or osteoporosis","volume":"104","author":"Planas","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.007_bib0110","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.007_bib0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2011.03.111","article-title":"Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer","volume":"186","author":"Saylor","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.007_bib0120","unstructured":"Dietary supplement fact sheet: vitamin D. National Institutes of Health, Office of Dietary Supplements Web site. http:\/\/ods.od.nih.gov\/factsheets\/vitamind."},{"key":"10.1016\/j.eururo.2012.09.007_bib0125","unstructured":"Vitamin D and calcium: updated dietary reference intakes. Health Canada Web site. http:\/\/www.hc-sc.gc.ca\/fn-an\/nutrition\/vitamin\/vita-d-eng.php."},{"key":"10.1016\/j.eururo.2012.09.007_bib0130","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2012.09.007_bib0135","unstructured":"Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004."},{"key":"10.1016\/j.eururo.2012.09.007_bib0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer","volume":"8","author":"Saylor","year":"2010","journal-title":"Natl Compr Canc Netw"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812010305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812010305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T17:50:01Z","timestamp":1542736201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812010305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0302283812010305"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.09.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}